Photobiomodulation Therapy as a Possible New Approach in COVID-19: A Systematic Review

Brenda Thaynne Lima de Matos1, Daniela Vieira Buchaim2,3, Karina Torres Pomini1,2

  • 1Department of Biological Sciences, Bauru School of Dentistry (FOB/USP), University of São Paulo, Bauru 17012-901, SP, Brazil.

Insights

Photobiomodulation therapy (PBMT) may aid COVID-19 patients by boosting immunity and reducing inflammation. Further clinical trials are needed to confirm PBMT

Area of Science:

  • Medical Science
  • Immunology
  • Virology

Background:

  • COVID-19 pandemic declared in March 2020.
  • Complications often stem from weakened immune responses and excessive inflammation.
  • Photobiomodulation therapy (PBMT) is explored for its potential to modulate immunity and aid tissue repair.

Purpose of the Study:

  • To systematically review existing literature on the efficacy of PBMT for COVID-19 patients.
  • To assess PBMT's potential role in managing COVID-19 symptoms and complications.
  • To identify research gaps and the need for further clinical investigation.

Main Methods:

  • Systematic literature search of PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar.
  • Keywords used: "low-level laser therapy OR photobiomodulation therapy AND COVID-19".
  • Inclusion criteria: Full-text English articles from Jan 2020 to Jan 2021; exclusion of non-full-text, reviews, and other non-primary research formats.

Main Results:

  • Ten articles were included for qualitative synthesis.
  • Commentaries discussed PBMT's role in COVID-19 pathogenesis.
  • In vitro studies showed PBMT's potential in thrombosis prevention and wound healing.
  • Case reports and series indicated PBMT improved respiratory and inflammatory markers in COVID-19 patients.
  • One clinical trial showed PBMT improved diaphragm function and ventilation despite no significant difference in ICU stay.

Conclusions:

  • PBMT shows promise as an adjunctive therapy for COVID-19.
  • Evidence suggests PBMT may improve immune response, tissue repair, and reduce inflammation.
  • More rigorous clinical trials are necessary to establish definitive evidence for PBMT in COVID-19 treatment.